

VSN Laboratories Private Limited

September 04, 2024

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long Term Bank Facilities	16.30	CARE B-; Stable; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

CARE Ratings Ltd. had, vide its press release dated July 17, 2023, placed the rating(s) of VSN Laboratories Private Limited (VLPL) under the 'issuer non-cooperating' category as VLPL had failed to provide information for monitoring of the rating. VLPL continues to be non-cooperative despite repeated requests for submission of information through e-mails, phone calls and a letter/email dated June 01, 2024, June 11, 2024, June 21, 2024.

In line with the extant SEBI guidelines, CARE Ratings Ltd. has reviewed the rating on the basis of the best available information which however, in CARE Ratings Ltd.'s opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

Analytical approach: Standalone

Outlook: Stable

Detailed description of the key rating drivers:

Please refer to PR dated July 17, 2023

Applicable criteria

CARE Ratings' criteria on information adequacy risk and issuer non-cooperation
Policy on default recognition
Criteria on assigning outlook and credit watch

About the company

VSN Laboratories Private Limited (VLPL) was incorporated on June 01, 2009 by Mr.V.Nageswara Rao along with his wife Mrs.V.Padmavathi for manufacturing of Active Pharmaceutical Ingredients (APIs). In FY18 four new promoters, Mrs.K.Indira, Mr.K.Madhusudhan Rao. Bhuviteja Enterprises (India) Private Limited and Ms.K.Tejaswini, joined the company. The company was originally registered as Lucid Life Sciences Private Limited and subsequently the name of the company was changed to the current nomenclature i.e. VSN on December 18th, 2009. The company started with its trial runs in the month of February 2016; however, the commercial production was commenced on May 02, 2016 with a total installed capacity of 240 kilolitres per annum at its manufacturing unit located in Krishna District of Andhra Pradesh. The company has expanded its manufacturing unit and increased the installed capacity to 72KL per month from June 2018. The facilities of VSN are incorporated as per Current Good Manufacturing Practices (CGMP) standards. VSN is manufacturing APIs with drugs portfolio like pantaprazole, triazole alcohol and omeprazole and others. These are used for the treatment of gastroesophageal reflux diseases, seasonal allergies, nausea, cholesterol, hypertension, etc. The company sources raw materials required for manufacturing of APIs from vendors based in Hyderabad and Mumbai. VSN is supplying APIs to variety of domestic formulators (mainly private pharmaceutical companies). VSN also has an on-site well-equipped Research and Development (R&D) Centre which is continuously involved in process development, trouble shooting and process optimisation of the drugs.

^{*}Issuer did not cooperate; based on best available information.

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications



Brief Financials (₹ crore)	March 31, 2022 (A)	March 31, 2023 (A)
Total operating income	21.72	19.99
PBILDT	2.76	1.31
PAT	0.11	0.03
Overall gearing (times)	5.20	5.40
Interest coverage (times)	1.42	1.16

A: Audited; Note: 'the above results are latest financial results available'

Status of non-cooperation with previous CRA: Brickwork has continued the rating assigned to the bank facilities of VLPL into Issuer Not Cooperating category vide press release dated April 05, 2024 on account of its inability to carry out a review in the absence of the requisite information from the company.

Any other information: Not Applicable

Rating history for last three years: Please refer Annexure-2

Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in

Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD- MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT- Cash Credit		•	-	-	5.02	CARE B-; Stable; ISSUER NOT COOPERATING*
Fund-based - LT- Term Loan		-	-	January, 2026	11.28	CARE B-; Stable; ISSUER NOT COOPERATING*

^{*}Issuer did not cooperate; Based on best available information



Annexure-2: Rating history for the last three years

	Name of	Current Ratings			Rating History			
Sr. No	the Instrumen t/Bank Facilities	Ty pe	Amount Outstandin g (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Fund-based - LT-Term Loan	LT	11.28	CARE B-; Stable; ISSUER NOT COOPERATING*	-	1)CARE B-; Stable; ISSUER NOT COOPERATIN G* (17-Jul-23)	1)CARE B-; Stable; ISSUER NOT COOPERATIN G* (28-Jun-22)	1)CARE B-; Stable; ISSUER NOT COOPERATIN G* (28-Apr-21)
2	Fund-based - LT-Cash Credit	LT	5.02	CARE B-; Stable; ISSUER NOT COOPERATING*	-	1)CARE B-; Stable; ISSUER NOT COOPERATIN G* (17-Jul-23)	1)CARE B-; Stable; ISSUER NOT COOPERATIN G* (28-Jun-22)	1)CARE B-; Stable; ISSUER NOT COOPERATIN G* (28-Apr-21)

^{*}Issuer did not cooperate; Based on best available information

Annexure-3: Detailed explanation of the covenants of the rated instruments/facilities: Not Applicable

Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Cash Credit	Simple
2	Fund-based - LT-Term Loan	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please click here

Note on complexity levels of the rated instrument: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

LT: Long term



Contact us

Media Contact

Mradul Mishra Director

CARE Ratings Limited Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

Relationship Contact

Saikat Roy Senior Director

CARE Ratings Limited Phone: 91 22 6754 3404

E-mail: saikat.roy@careedge.in

Analytical Contacts

Shachee Vyas **Assistant Director**

CARE Ratings Limited

Phone: 079-40265665

E-mail: shachee.tripathi@careedge.in

Foram Dhruv Joshi Lead Analyst

CARE Ratings Limited Phone: 079-40265687

E-mail: foram.dave@careedge.in

Kush Tilva Associate Analyst **CARE Ratings Limited** E-mail: kush.tilva@careedge.in

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

> For detailed Rationale Report and subscription information, please visit www.careedge.in